NASDAQ$KNSA
Kiniksa Pharmaceuticals Ltd · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Reported first quarter 2021 financial results and recent corporate and portfolio activity.
Kiniksa reported first quarter results, highlighting the FDA approval of ARCALYST for recurrent pericarditis and progress in their broader portfolio of immune-modulating assets, including mavrilimumab and KPL-404.
- ARCALYST launched as the first and only FDA-approved therapy for recurrent pericarditis.
- Mavrilimumab Phase 2 data in severe COVID-19 demonstrated a reduction in mechanical ventilation and death at Day 29; Phase 3 enrollment ongoing.
- Final KPL-404 Phase 1 data support further development in patients; Phase 2 proof-of-concept trial initiation planned for 2H 2021.
- Cash reserves of approximately $264 million.
Headline financials
Revenue & EPS history
Kiniksa · Revenue · Quarterly
$214M
Revenue by segment
Kiniksa · $64.8M total across 1 segment · Q3 2023
- ARCALYST$64.8M+94.0%100.0%
Forward guidance
Kiniksa is focused on the launch of ARCALYST and are confident in their commercialization strategy.
Tailwinds
- Engaging with the FDA and other government agencies to identify pathways for the potential accelerated availability of mavrilimumab as a therapeutic option for severe COVID-19 patients.
- Initiating Phase 2 proof-of-concept trial of KPL-404 in rheumatoid arthritis in the second half of 2021.
- KPL-404 has the potential to address a broad range of autoimmune diseases.
- Vixarelimab is the only monoclonal antibody in development that targets both interleukin-31 (IL-31) and oncostatin M (OSM) pathways simultaneously.
- Expectation about cash reserves funding current operating plan into 2023.
Headwinds
- Delays or difficulty in enrollment of patients in, and activation or continuation of sites for, clinical trials.
- Amendments to clinical trial protocols initiated or required by regulatory authorities.
- Delays or difficulty in completing clinical trials, including as a result of the COVID-19 pandemic.
- Potential for changes between final data and any preliminary, interim, top-line or other data from clinical trials conducted by us or third parties.
- Inability to replicate in later clinical trials the positive final data from earlier clinical trials or studies.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
+5.3%
Avg return
Earnings day
+5.2%
Avg return
5 days after
+7.8%
Avg return
30 days after
55%
17 / 31 earnings
Positive
+45.8%
Q3 2021
Best reaction
-16.6%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +23.5% | +26.7% | +16.6% | |
| Q4 2025 | -4.7% | -6.1% | -1.3% | |
| Q3 2025 | -2.9% | -8.8% | +4.8% | |
| Q1 2025 | +20.5% | +28.8% | +26.6% | |
| Q4 2024 | +0.5% | +3.3% | +19.0% | |
| Q3 2024 | -16.6% | -18.5% | -19.1% | |
| Q2 2024 | +17.8% | +22.1% | +22.5% | |
| Q1 2024 | +4.4% | +4.6% | +12.1% | |
| Q4 2023 | +1.2% | -3.4% | -5.6% | |
| Q3 2023 | -3.4% | +3.3% | +3.1% | |
| Q2 2023 | +35.2% | +26.8% | +18.1% | |
| Q1 2023 | +24.2% | +24.7% | +29.0% | |
| Q4 2022 | -5.6% | -7.8% | -19.7% | |
| Q3 2022 | +8.6% | +21.7% | +49.3% | |
| Q2 2022 | +17.3% | +29.9% | +14.7% | |
| Q1 2022 | +5.1% | -6.8% | -18.4% | |
| Q4 2021 | -6.8% | -3.4% | -7.2% | |
| Q3 2021 | +45.8% | +41.8% | +8.8% | |
| Q2 2021 | -1.4% | -5.4% | -10.0% | |
| Q1 2021 | -9.0% | -11.4% | -19.4% | |
| Q4 2020 | -6.3% | -11.9% | -28.5% | |
| Q3 2020 | -5.9% | -7.2% | +9.6% | |
| Q2 2020 | +0.8% | -1.2% | -14.7% | |
| Q1 2020 | -7.0% | -9.2% | -0.6% | |
| Q4 2019 | -0.7% | +6.1% | -29.5% | |
| Q3 2019 | +15.7% | +24.5% | +80.8% | |
| Q2 2019 | -2.4% | -12.1% | -9.4% | |
| Q1 2019 | +8.2% | +2.6% | +6.5% | |
| Q4 2018 | -6.1% | -0.2% | +20.2% | |
| Q3 2018 | +11.9% | +5.1% | +6.2% | |
| Q2 2018 | +1.7% | +3.5% | +78.2% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro